Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Four Ring Pharmaceutical, has had several of its products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025), which may influence future sales but will not significantly impact the company's current operating performance [1] Group 1: Product Inclusion - A total of 34 products from the company's subsidiaries, including Beijing Huasu, Shandong Huasu, and Duoduo Pharmaceutical, have been included in the 2025 drug catalog [1] - New products added to the catalog include Sulfate Fish Protein Injection and Compound Pancreatin Powder [1] - Products previously included in the 2024 catalog, such as Bisoprolol Fumarate Tablets and Benidipine Hydrochloride Tablets, will continue to be listed [1] Group 2: Product Changes - Beijing Huasu's "Compound Chlorphentermine Injection" has been removed from the 2025 catalog [1] - Duoduo Pharmaceutical's "Ambroxol Hydrochloride Injection" has been newly included in the catalog [1] Group 3: Market Impact - The future sales of the included products may be affected by changes in the market environment and other factors [1] - The company states that these changes will not have a major impact on its current operating performance [1]

Core Viewpoint - Lijun Group (000513.SZ) announced that it has 194 products included in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's operating performance in the future [1] Group 1: Product Inclusion - The group has 194 products in the National Medical Insurance Directory, including 92 Class A and 102 Class B products [1] - Injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - Injectable Triptorelin acetate microspheres have a new indication added, and Injectable Esomeprazole sodium has successfully renewed its contract [1] - No products from the group have exited the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Directory is expected to help expand the market and improve drug accessibility [1] - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. has announced that five of its products have been included in the National Medical Insurance Directory for 2025, which is expected to enhance market expansion and sales scale for the company [1][2]. Group 1: Product Inclusion - Five products from the company and its subsidiaries have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory for 2025 [1]. - The total sales of these products for the year 2024 are approximately 51.69 million yuan, and for the first half of 2025, the sales are approximately 309.75 million yuan, accounting for about 0.24% and 3.41% of the company's revenue during the respective periods [1]. Group 2: Impact on the Company - The inclusion of products in the 2025 Drug Directory is expected to facilitate the company's market network expansion and increase sales scale, although the exact impact on operating performance cannot be estimated at this time [2]. - The National Medical Insurance Directory will officially take effect on January 1, 2026, with further details on payment standards and reimbursement rules to be provided by relevant government departments [2].

Core Viewpoint - Shandong Buchang Pharmaceutical Co., Ltd. successfully renewed the inclusion of its products Xuanfei Baidu Granules and Danhong Injection in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's market position and sales performance [1][3]. Product Information - Xuanfei Baidu Granules are indicated for clearing lung heat and detoxifying, used for damp-heat obstructing the lungs, with symptoms including fever, cough, and shortness of breath [1]. - Danhong Injection is used for promoting blood circulation and alleviating pain, indicated for conditions such as chest pain and stroke, with symptoms including chest tightness and limb numbness [2]. Sales Impact - The National Medical Insurance Directory will be officially implemented on January 1, 2026, and the sales performance of the drugs may be influenced by various market factors, indicating a level of uncertainty [3].

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market position [1][3]. Product Information - Product Name: Yiqi Qingfei Granules - Drug Classification Code: ZA09G - Drug Type: Traditional Chinese Medicine (TCM) - Registration Category: TCM Class 3.2 - Dosage Form: Granules - Agreement Validity: January 1, 2026, to December 31, 2027 - Indications: Used for symptoms related to Qi and Yin deficiency, spleen deficiency, and dampness, including fatigue, shortness of breath, dry cough, and gastrointestinal discomfort [1][2]. Impact on the Company - Yiqi Qingfei Granules received its drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and sales activities. The inclusion in the National Medical Insurance Directory is expected to have a positive impact on the company's product layout in the respiratory field, although it is not anticipated to significantly affect short-term operating performance [3].

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. and its subsidiaries have five products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, which is expected to enhance market expansion and sales scale for the company [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued a notice regarding the 2025 drug catalog [1] - The inclusion of the company's products in the 2025 drug catalog is anticipated to positively impact the company's market network and sales [1] - The official implementation date for the 2025 drug catalog is set for January 1, 2026, with further details on reimbursement standards to be provided by relevant government departments [1]

Core Insights - The announcement from Lijun Pharmaceutical (01513) indicates that a total of 194 products from the company have been included in the National Medical Insurance Catalog for 2025, with 92 classified as Category A and 102 as Category B [1] Group 1 - The inclusion of Lijun Pharmaceutical's products in the National Medical Insurance Catalog is significant for the company's market positioning and revenue potential [1] - Notably, the injectable Aripiprazole microspheres have been included in the catalog for the first time through negotiations, which may enhance its market access [1] - The injectable Triptorelin acetate microspheres have received an additional indication, potentially expanding its usage and sales opportunities [1] Group 2 - The injectable Esomeprazole sodium has successfully renewed its contract, ensuring continued reimbursement and market presence [1]

自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 本集團未有產品退出《國家醫保目錄》。本集团前述產品納入《國家醫保目錄》有助於後 續擴大市場及提高藥品可及性，預計未來將對本公司的經營業績產生積極影響。此版《國 家醫保目錄》將於2026年1月1日正式執行，預計不會對本公司当期經營業績產生重大影響。 2 醫保支付標準、醫保報銷細則等相關資訊需以國家醫保局等相關部門公示的資訊為准。公 司產品未來銷售情況受醫藥行業政策變動、市場環境變化等影響，具有一定的不確定性。 敬請廣大投資者審慎決策，注意投資風險。 公司產品納入國家醫保目錄 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬公 司，統稱「本集團」）自願作出，以告知本公司股東及潛在投資者本集團最新業務更新。 2025年12月7日，國家醫保局、人力資源社會保障部發佈了《國家基本醫療保險、生育保 險和工傷保險藥品目錄（2025年）》（醫保 ...

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have announced the inclusion of Nanjing Haichen Pharmaceutical's injectable Landeolol hydrochloride (50mg) in the National Medical Insurance Directory for 2025, and the first-time inclusion of injectable Landeolol hydrochloride (150mg) [1] Group 1 - Landeolol hydrochloride is a new generation of rapid-acting, ultra-short-acting, highly selective β1 receptor blocker, with a selectivity ratio of approximately 255 times for β1 over β2 receptors, and 8 times more selective than another ultra-short-acting β blocker, Esmolol [2] - The drug has a rapid onset of action (1 to 6 minutes post-administration), a short half-life of about 4 minutes, and minimal negative impact on cardiac hemodynamics and respiratory function [2] - Landeolol is recommended for controlling ventricular rate in acute heart failure patients according to the 2023 National Heart Failure Guidelines, and is also a recommended drug for acute atrial fibrillation in the 2024 Chinese Emergency Management Guidelines [2] Group 2 - The product is projected to achieve sales revenue of 337.77 million yuan in 2024, accounting for 67.27% of the company's total revenue, making it the company's main product [2]

Core Viewpoint - The announcement by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security regarding the new National Medical Insurance Catalog (2025 version) includes the successful renewal of the company's环泊酚注射液 and the addition of安瑞克芬注射液, which is a significant development for the company and its product portfolio [1] Group 1 - The National Medical Insurance Catalog (2025 version) was officially released on December 7, 2025 [1] - The company has successfully renewed the listing of环泊酚注射液 and has added安瑞克芬注射液 to the new catalog [1] - 安瑞克芬注射液 is a self-developed high-selectivity peripheral kappa opioid receptor agonist and is the first non-narcotic prescription opioid analgesic approved for pain relief without being classified as a controlled substance [1] Group 2 - The company now has four class 1 innovative drugs included in the National Medical Insurance Catalog (2025 version), which are环泊酚注射液, 安瑞克芬注射液, 苯磺酸克利加巴林胶囊, and 考格列汀片 [1]